Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Duality Biotherapeutics / Equity Capital Markets

<ul>
<li>Duality Biotherapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$300m via a Hong Kong listing.</li>
<li>In this note, we examine the company's two core products, namely DB-1313 (HER2 ADC) and DB-1311 (B7-H3 ADC). We think the company's products are not yet convincing.</li>
<li>While the management has expertise as biotech investors, biotech-related operational experience seems to be lacking.</li>
</ul>


Duality Biotherapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$300m via a Hong Kong listing.
In this note, we examine the company's two core products, namely DB-1313 (HER2 ADC) and DB-1311 (B7-H3 ADC). We think the company's products are not yet convincing.
While the management has expertise as biotech investors, biotech-related operational experience seems to be lacking.


Duality Biotherapeutics (映恩生物) Pre-IPO: Too Early, Too Ambitious

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Duality Biotherapeutics (DUA HK)

Duality Biotherapeutics (映恩生物) Pre-IPO: Too Early, Too Ambitious

Duality biotherapeutics is looking to raise USD 300m in a Hong Kong listing. We look at its core products and key products, as well as its investor...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)